Stocktoria
Emergent BioSolutions Inc. EBS
Emergent BioSolutions Inc. (EBS) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $742.9M at a 7.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.57 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.402 |
| Retained earnings / assets | -0.121 |
| EBIT / assets | 0.076 |
| Equity / liabilities | 0.657 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 6/9 | 1.76 | 18.9 | +23.6% |
| KNSA | Kiniksa Pharmaceuticals International, plc | 6/9 | 5.08 | 77.2 | +60.1% |
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
FAQ
Is EBS financially healthy?
Emergent BioSolutions Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does EBS pay a dividend?
No, Emergent BioSolutions Inc. does not currently pay a dividend.
How profitable is EBS?
In FY2025, Emergent BioSolutions Inc. had a net margin of 7.1% and a return on equity of 10.1%.
Is EBS overvalued or undervalued?
Emergent BioSolutions Inc. trades at about 4.9× trailing earnings — below its 10-year norm (10-year range 11.5×–53.0×, median 28.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for EBS?
The average Wall-Street price target for Emergent BioSolutions Inc. is $12.00, about 163.7% above the recent price, from 2 analysts.
Is EBS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Emergent BioSolutions Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 8.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.